By using exogenous EGF and pharmacological inhibition of EGFR, it was shown that EGFR could control PD-L1 expression through a MAPK/Akt/STAT-dependent mechanism in NSCLC [141,142,143,144,145]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.